Navigation Links
Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
Date:9/20/2007

TORONTO, Sept. 20 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI) today announced the market launch of its EAA(TM) Endotoxin Activity Assay, a rapid diagnostic product for sepsis, in Germany through A. Menarini Diagnostics Deutschland ("Menarini"), a division of the Italian Menarini Group. Sepsis is the third most common cause of death in Germany with 60,000 victims each year. The treatment of severe sepsis consumes about one third of intensive care units' budgets in Germany ((euro) 1.7 billion per year), emphasizing the need for early detection of sepsis.

"The German launch represents a significant milestone in the commercialization of our EAA(TM) rapid sepsis diagnostic and follows several months of extensive research by our partner Menarini," stated Dr. Paul Walker, President & CEO of Spectral. "Germany is the largest healthcare market in the EU and we are quite confident that with Menarini's broad and experienced sales presence we are well positioned to make a successful entry into this market and set the stage for expansion into the rest of Europe in 2008."

Menarini Diagnostics was founded in 1976 as a division of A. Menarini Industrie Farmaceutiche Riunite of Florence, Italy, a multinational healthcare company with annual revenues of more than 2.2 billion Euros, with eleven wholly owned subsidiaries in Austria, Belgium, France, Germany, Greece, Italy, the Netherlands, Portugal, Spain, United Kingdom and Sweden. Menarini Diagnostics had 2005 consolidated revenues of approximately 256 million Euros and currently employs approximately 700 people, 75% of whom are dedicated to marketing, sales, after-sales service and customer care activities.

Spectral is a developer of innovative technologies for comprehensive disease management. Spectral technologies provide accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Current products include Spectral's FDA approved rapid diagnostic for West Nile Virus (RapidWN(TM)) and its FDA approved rapid diagnostic for sepsis (EAA(TM)), as well as a range of other biological reagents.

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.


'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Jellyfish partners for sales tracking technology
2. GE Healthcare partners with UNC on breast cancer imaging research
3. Manufacturing partnership will move into biotech and biomedical spaces
4. Fergus joins Baird Venture Partners, Caden Bio
5. Avolte Venture Partners reaches capital goal
6. NimbleGen partners with UK biotech firm
7. Big pharma seeks Wisconsin biotech partnerships
8. Thompson in partnership to build ethanol plant
9. Johnson Controls partners on car satellite linkup
10. Doyle, WARF announce partnership to lure stem cell companies
11. GE partner allows real-time access to patient data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that in a published evaluation of multiple immunoassay-based threat detection technologies by ... Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have ...
Breaking Biology Technology:
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... Feb. 3, 2017 A new independent identity ... Partners, LLP (IdSP) . Designed to fill a critical ... identity market, founding partners Mark Crego and ... years just in identity expertise that span federal governments, ... leadership. The Crego-Kephart combined expertise has a common theme ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
Breaking Biology News(10 mins):